Nisa Investment Advisors LLC Acquires 1,020 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS)

Nisa Investment Advisors LLC lifted its stake in BioLife Solutions, Inc. (NASDAQ:BLFS) by 167.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,630 shares of the medical equipment provider’s stock after acquiring an additional 1,020 shares during the period. Nisa Investment Advisors LLC’s holdings in BioLife Solutions were worth $26,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in BLFS. Allspring Global Investments Holdings LLC lifted its holdings in BioLife Solutions by 88.4% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 11,346 shares of the medical equipment provider’s stock worth $157,000 after purchasing an additional 5,324 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of BioLife Solutions by 8.1% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 15,622 shares of the medical equipment provider’s stock valued at $216,000 after acquiring an additional 1,164 shares during the period. Everence Capital Management Inc. purchased a new position in BioLife Solutions during the third quarter valued at approximately $218,000. Dark Forest Capital Management LP bought a new stake in BioLife Solutions during the 3rd quarter worth approximately $223,000. Finally, Illinois Municipal Retirement Fund purchased a new stake in BioLife Solutions in the 3rd quarter worth approximately $270,000. 93.24% of the stock is currently owned by hedge funds and other institutional investors.

BioLife Solutions Stock Up 5.9 %

Shares of NASDAQ BLFS opened at $16.80 on Tuesday. The business has a 50-day moving average of $17.40 and a 200-day moving average of $15.39. The firm has a market capitalization of $761.04 million, a price-to-earnings ratio of -11.05 and a beta of 1.67. The company has a current ratio of 2.86, a quick ratio of 1.83 and a debt-to-equity ratio of 0.06. BioLife Solutions, Inc. has a 12 month low of $8.92 and a 12 month high of $24.50.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, February 29th. The medical equipment provider reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.02. The business had revenue of $32.73 million during the quarter, compared to analysts’ expectations of $32.70 million. BioLife Solutions had a negative net margin of 46.37% and a negative return on equity of 13.36%. Sell-side analysts expect that BioLife Solutions, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $15.67, for a total transaction of $156,700.00. Following the sale, the chief marketing officer now owns 129,644 shares in the company, valued at $2,031,521.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Amy Duross sold 6,135 shares of the company’s stock in a transaction on Tuesday, March 12th. The shares were sold at an average price of $16.86, for a total value of $103,436.10. Following the completion of the sale, the director now owns 34,508 shares of the company’s stock, valued at approximately $581,804.88. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CMO Todd Berard sold 10,000 shares of the stock in a transaction on Monday, April 15th. The shares were sold at an average price of $15.67, for a total transaction of $156,700.00. Following the transaction, the chief marketing officer now directly owns 129,644 shares in the company, valued at approximately $2,031,521.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 31,366 shares of company stock worth $521,392. Corporate insiders own 2.70% of the company’s stock.

Analysts Set New Price Targets

Separately, Jefferies Financial Group started coverage on shares of BioLife Solutions in a research report on Thursday, April 4th. They set a “buy” rating and a $22.00 price target for the company. One analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, BioLife Solutions currently has a consensus rating of “Moderate Buy” and a consensus target price of $23.40.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.